Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells

Clinical Cancer Research

Volumn 15, Issue 18, 2009, Pages 5852-5860

  Yvon, Eric ^a,f   Del Vecchio, Michele ^c   Savoldo, Barbara ^a   Hoyos, Valentina ^a   Dutour, Aurélie ^e   Anichini, Andrea ^d   Dotti, Gianpietro ^a,b   Brenner, Malcolm K ^a,b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c IRCCS   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e CENTRE LÉON BÉRARD   (France)

^f CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD28 ANTIGEN; GAMMA INTERFERON; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2; INTERLEUKIN 2; INTERLEUKIN 5; LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER SURVIVAL; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPLASM; EXTRACELLULAR MATRIX; GENE TARGETING; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

EID: 70349439277     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3163     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Bajetta E, Del Vecchio M, Bernard-Marty C, et al. Metastatic melanoma: chemotherapy. Semin Oncol 2002;29:427-445
3. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308.
4. Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006;24:5060-5069 (Pubitemid 46631410)
5. Butler MO, Lee JS, Ansen S, et al. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res 2007;13:1857-1867 (Pubitemid 46952956)
6. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 2004;101:14639-14645
7. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-129
8. Ohnmacht GA, Marincola FM. Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma. J Cell Physiol 2000;182:332-338 (Pubitemid 30054366)
9. Pule M, Finney H, Lawson A. Artificial T-cell receptors. Cytotherapy 2003;5:211-226
10. Haynes NM, Trapani JA, Teng MW, et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 2002;100:3155-3163
11. Yun CO, Nolan KF, Beecham EJ, Reisfeld RA, Junghans P. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia 2000;2:449-459
12. Livingston P. Ganglioside vaccines with emphasis on GM2. Semin Oncol 1998;25:636-645
13. Tsuchida T, Sazton RE, Morton DL, Irie RF. Gangliosides of human melanoma. Cancer 1989;63:1166-1174
14. Albino AP, Sozzi G, Nanus DM, Jhanwar SC, Houghton AN. Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene 1992;7:2315-2321
15. Ravindranath MH, Muthugounder S, Presser N. Ganglioside signatures of primary and nodal metastatic melanoma cell lines from the same patient. Melanoma Res 2008;18:47-55. (Pubitemid 351628056)
16. Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-1044 (Pubitemid 24145334)
17. Ragupathi G, Livingston PO, Hood C, et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 2003;9:5214-5220 (Pubitemid 37413571)
18. Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005;12:933-941 (Pubitemid 41614489)
19. Yvon ES, Vigouroux S, Rousseau RF, et al. Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells. Blood 2003;102:3815-3821 (Pubitemid 37409406)
20. Gottschalk S, Edwards OL, Sili U, et al. Genearting CTLs against subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003;101:1905-1912 (Pubitemid 36237592)
21. Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30 artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 2007;110:2620-2630 (Pubitemid 47523186)
22. Vera J, Savoldo B, Vigouroux S, et al. T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 2006;108:3890-3897 (Pubitemid 44864573)
23. Rossig C, Bollard CM, Nuchtern JG. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer 2001;94:228-236
24. Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 1992;52:4342-4347
25. Murray JL, Cunningham JE, Brewer H, et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 1994;12:184-193 (Pubitemid 24020639)
26. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in neuroblastoma patients. Nat Med 2008;14:1264-1270
27. Cheresh DA, Harper JR, Schulz G, Reisfeld RA. Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of the human melanoma cells. Proc Natl Acad Sci U S A 1984;81:5767-5771 (Pubitemid 14018484)
28. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 2001;491:369-402. (Pubitemid 32595136)
29. Hersey P, Jamal O, Henderson C, Zardawi I, D'Alessandro G. Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma. Int J Cancer 1988;41:336-343 (Pubitemid 18080784)
30. Weijtens ME, Hart EH, Bolhuis RL. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther 2000;7:35-42.
31. Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RLH. T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol 2005;174:7853-7858 (Pubitemid 40806294)
32. Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004;18:676-684 (Pubitemid 38500185)
33. Heemskerk MHM, Hoogeboom M, Hagedoorn R, Kester MGD, Willemze R, Falkenburg FJH. Reprogramming of virus-specific T cells into Leukemia-reactive T cells using T cell receptor gene transfert. J Exp Med 2004;199:885-894 (Pubitemid 38481080)